Form 4: Director Christy Jones Sells Beta Bionics Shares
Statement of Changes in Beneficial Ownership
Director Christy Jones sold 2,811 shares of Beta Bionics, Inc. common stock on June 4, 2026, via a Rule 10b5-1 trading plan.
Summary
- Director Christy Jones executed a sale of 2,811 shares of Beta Bionics, Inc. (BBNX) common stock.
- The transaction occurred on June 4, 2026, at a price of $14.00 per share.
- Following this transaction, the reporting person retains beneficial ownership of 27,400 shares.
- The sale was conducted pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 19, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-arranged 10b5-1 plan, which is a standard and transparent method for insider divestment.
Positives
- The sale was executed under a pre-planned Rule 10b5-1 program, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.
Negatives
- The transaction represents a reduction in the director's direct equity stake in the company.
Risks
- Insider selling can sometimes be perceived negatively by the market as a signal of management's view on current valuation.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that insider sales via 10b5-1 plans are routine corporate governance events and generally do not reflect a change in the company's fundamental outlook or strategic direction.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage personal liquidity while maintaining compliance with SEC regulations.
Stakeholder Impact
- Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the director's total holdings.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 2026-02-19 | Date the Rule 10b5-1 trading plan was adopted. |
| 2026-06-04 | Date of the reported stock sale transaction. |
| 2026-06-05 | Date the Form 4 was signed and filed. |
Keywords
Beta Bionics, BBNX, Insider Trading, Form 4, Director Sale, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.